Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNS Marinus Pharmaceuticals	$0.55 -0.2%	$0.55	$0.22 ▼ $1.97	$30.32M	1.03	1.92 million shs	260 shs
NKTR Nektar Therapeutics	$24.78 -0.7%	$15.75	$6.48 ▼ $37.38	$308.08M	0.94	522,309 shs	177,377 shs
OMER Omeros	$3.77 +12.2%	$3.38	$2.95 ▼ $13.60	$220.83M	2.16	746,306 shs	333,811 shs
PRTK Paratek Pharmaceuticals	$2.23	$2.22	$1.29 ▼ $3.65	$127.82M	1.7	724,253 shs	N/A

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNS Marinus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-61.60%
NKTR Nektar Therapeutics	0.00%	-0.28%	+193.07%	+165.64%	+19.62%
OMER Omeros	0.00%	-7.95%	+4.67%	-49.85%	-31.15%
PRTK Paratek Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MRNS Marinus Pharmaceuticals	2.1032 of 5 stars	3.2	0.0	0.0	4.2	0.0	1.7	0.6
NKTR Nektar Therapeutics	4.0817 of 5 stars	3.4	2.0	0.0	4.2	3.3	2.5	0.0
OMER Omeros	3.7808 of 5 stars	3.4	0.0	0.0	4.4	2.9	1.7	0.6
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRNS Marinus Pharmaceuticals	2.40	Hold	$3.92	613.29% Upside
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	256.53% Upside
OMER Omeros	2.83	Moderate Buy	$18.00	377.45% Upside
PRTK Paratek Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OMER, NKTR, PRTK, and MRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
6/30/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/27/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00
6/10/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/16/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
5/12/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/7/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRNS Marinus Pharmaceuticals	$30.99M	0.98	N/A	N/A	$0.31 per share	1.77
NKTR Nektar Therapeutics	$98.43M	3.12	N/A	N/A	$4.94 per share	5.02
OMER Omeros	N/A	N/A	N/A	N/A	($3.15) per share	N/A
PRTK Paratek Pharmaceuticals	$160.27M	0.80	N/A	N/A	($3.08) per share	-0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRNS Marinus Pharmaceuticals	-$141.40M	-$2.47	N/A	N/A	N/A	-446.48%	-7,831.35%	-120.74%	8/11/2025 (Estimated)
NKTR Nektar Therapeutics	-$118.96M	-$9.60	N/A	N/A	N/A	-152.49%	-329.54%	-55.24%	8/6/2025 (Estimated)
OMER Omeros	-$156.82M	-$2.65	N/A	N/A	N/A	N/A	N/A	-59.68%	8/6/2025 (Estimated)
PRTK Paratek Pharmaceuticals	-$63.57M	-$1.10	N/A	∞	N/A	-35.44%	N/A	-40.05%	N/A

Latest OMER, NKTR, PRTK, and MRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NKTR Nektar Therapeutics	-$2.58	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	OMER Omeros	-$0.46	N/A	N/A	N/A	$0.31 million	N/A
5/15/2025	Q1 2025	OMER Omeros	-$0.60	-$0.65	-$0.05	-$0.58	$0.40 million	N/A
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRNS Marinus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRNS Marinus Pharmaceuticals	N/A	1.66	1.47
NKTR Nektar Therapeutics	N/A	3.24	3.24
OMER Omeros	N/A	1.16	1.16
PRTK Paratek Pharmaceuticals	N/A	0.52	0.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRNS Marinus Pharmaceuticals	98.80%
NKTR Nektar Therapeutics	75.88%
OMER Omeros	48.79%
PRTK Paratek Pharmaceuticals	53.60%

Insider Ownership

Company	Insider Ownership
MRNS Marinus Pharmaceuticals	5.46%
NKTR Nektar Therapeutics	3.71%
OMER Omeros	12.90%
PRTK Paratek Pharmaceuticals	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRNS Marinus Pharmaceuticals	110	55.22 million	52.20 million	Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.95 million	Optionable
OMER Omeros	210	58.59 million	51.04 million	Optionable
PRTK Paratek Pharmaceuticals	268	57.32 million	52.74 million	Optionable

OMER, NKTR, PRTK, and MRNS Headlines

Recent News About These Companies

Optinose CEO and other top executives exit after company's acquisition by Paratek

May 23, 2025 | bizjournals.com

Paratek expands commercial portfolio with Optinose

May 22, 2025 | msn.com

OptiNose Shareholders Approve Merger with Paratek

May 18, 2025 | investing.com

Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference

May 16, 2025 | globenewswire.com

How a Bucks County firm's multiyear pursuit of a partner led to a potential $330M deal

April 11, 2025 | bizjournals.com

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025

April 10, 2025 | globenewswire.com

Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M

March 21, 2025 | fiercepharma.comF

Paratek Pharmaceuticals to acquire Optinose in $330M transaction

March 21, 2025 | markets.businessinsider.com

Paratek boosts commercial portfolio in move to buy Optinose and its nasal spray

March 20, 2025 | endpts.comE

Optinose Shares Surge Premarket on Takeover Deal With Paratek

March 20, 2025 | marketwatch.com

Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities

November 14, 2024 | globenewswire.com

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral ...

November 9, 2024 | eagletribune.comE

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease

November 8, 2024 | globenewswire.com

Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024

October 14, 2024 | globenewswire.com

Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens

July 31, 2024 | globenewswire.com

Paratek looks to bolster pneumonia antibiotic Nuzyra with win in post-marketing study

July 19, 2024 | fiercepharma.comF

Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia

July 18, 2024 | globenewswire.com

Pharmaceuticals / Health Products Summary

April 4, 2024 | opensecrets.orgO

Paratek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPs

March 5, 2024 | markets.businessinsider.com

Mira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and Dates

February 24, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Catalysts Driving Plug Power’s Turnaround Case
By Jeffrey Neal Johnson | July 18, 2025
View 3 Catalysts Driving Plug Power’s Turnaround Case
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
3 Cloud Software Leaders Positioned for AI Upside
By Chris Markoch | July 10, 2025
View 3 Cloud Software Leaders Positioned for AI Upside
Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?
By Leo Miller | June 28, 2025
View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

OMER, NKTR, PRTK, and MRNS Company Descriptions

Marinus Pharmaceuticals NASDAQ:MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Nektar Therapeutics NASDAQ:NKTR

$24.65 -0.29 (-1.16%)

As of 11:17 AM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Omeros NASDAQ:OMER

$3.79 +0.43 (+12.77%)

As of 11:17 AM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time